Files and links (1)
Published, Version of Record (VoR)CC BY V4.0, Open
Journal article
Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review
Bioengineering (Basel), v 11(10), 1010
11 Oct 2024
PMID: 39451386
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Ocular surface disease (OSD) is a frequent disabling challenge among patients with glaucoma who use benzalkonium chloride (BAK)-containing topical glaucoma medications for prolonged periods. In this comprehensive review, we evaluated the prevalence of OSD and its management, focusing on both current and future alternatives. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria were used to assess a) the impact of active ingredients and preservatives on the ocular surface and b) the efficacy of preservative-free (PF) alternatives and adjunctive therapies. BAK-containing glaucoma medications were found to significantly contribute to OSD by increasing corneal staining, reducing tear film stability, and elevating ocular surface disease index (OSDI) scores. Transitioning to PF formulations or those with less cytotoxic preservatives, such as Polyquad (R) and SofZia (R), demonstrated a marked improvement in OSD symptoms. In particular, the use of adjunct cyclosporine A, through its anti-inflammatory and enhanced tear film stability actions, was shown to be very beneficial to the ocular surface. Therefore, the most effective management of OSD is multi-factorial, consisting of switching to PF or less cytotoxic medications, adjunct use of cyclosporine A, and early incorporation of glaucoma surgical treatments such as laser trabeculoplasty, trabeculectomy, glaucoma drainage devices, or minimally invasive glaucoma surgery (MIGS).
Metrics
Details
- Title
- Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review
- Creators
- Ozlem Evren Kemer - Bilkent UniversityPriya Mekala - The University of Texas Southwestern Medical CenterBhoomi Dave - Drexel University, College of MedicineKaranjit Singh Kooner - The University of Texas Southwestern Medical Center
- Publication Details
- Bioengineering (Basel), v 11(10), 1010
- Publisher
- Mdpi
- Number of pages
- 24
- Grant note
- UL1TR001105 / National Center for Advancing Translational Sciences of the National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS) Research to Prevent Blindness (RPB), New York, NY, USA; NIH/NEI Core Grant for Vision Research
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001341995700001
- Scopus ID
- 2-s2.0-85207666938
- Other Identifier
- 991022005887804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Biotechnology & Applied Microbiology
- Engineering, Biomedical